

REMARKS

This paper is filed in response to the Office Action mailed on June 29, 2004. Claim 11 has been cancelled; claims 1, 3 and 12 have been amended; claims 1-10 and 12-19 remain pending.

In the Office Action, claims 1, 3 and 12 as well as the specification are objected to as the full chemical name for TIMD is misspelled. In response, the specification, abstract and claims have been amended to correct the spelling errors thereby traversing these objections.

Next, claims 11 and 18 stand rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent No. 3,882,203, U.S. Patent No. 4,601,969 or U.S. Patent No. 4,195,997. In response, claim 11 has been cancelled and applicants respectfully submit that dependent claim 18, which depends from allowable claim 12, is not anticipated by any of the prior art references. Claim 12 is indicated as being allowable by the Patent Office and therefore claim 18 is allowable as well. Accordingly, applicants respectfully request that the anticipation rejection of claim 18 is improper and should be withdrawn.

Claim 1-10, 12-17 and 19 are indicated as being allowable. Applicants respectfully submit that claim 18 is allowable as well.

In view of the amendments in remarks set forth above, applicants respectfully submit that this application is in a condition for allowance and an early action so indicating is respectfully requested.


The Commissioner is authorized to charge any fee deficiency required by this paper, or credit any overpayment, to Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-9577

August 20, 2004

By:


Michael R. Hull
Reg. No. 35,902